FDMT. – 4D Molecular Therapeutics Inc
Float Short %
17.3
Margin Of Safety %
Put/Call OI Ratio
0.12
EPS Next Q Diff
-1.62
EPS Last/This Y
-0.28
EPS This/Next Y
-0.22
Price
7.97
Target Price
33.11
Analyst Recom
1.45
Performance Q
-24.33
Relative Volume
0.54
Beta
3
Ticker: FDMT
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | FDMT | 7.97 | 0.11 | 0.00 | 4726 |
| 2025-12-29 | FDMT | 7.67 | 0.11 | 0.00 | 4744 |
| 2025-12-30 | FDMT | 7.58 | 0.11 | 0.20 | 4752 |
| 2025-12-31 | FDMT | 7.48 | 0.11 | 160.00 | 4761 |
| 2026-01-02 | FDMT | 7.31 | 0.14 | 0.59 | 4909 |
| 2026-01-05 | FDMT | 7.31 | 0.15 | 0.04 | 4903 |
| 2026-01-06 | FDMT | 7.18 | 0.14 | 999.99 | 5097 |
| 2026-01-07 | FDMT | 7.78 | 0.14 | 1.25 | 5109 |
| 2026-01-08 | FDMT | 7.3 | 0.14 | 2.33 | 5107 |
| 2026-01-09 | FDMT | 7.51 | 0.15 | 0.40 | 5158 |
| 2026-01-12 | FDMT | 7.52 | 0.15 | 0.00 | 5162 |
| 2026-01-13 | FDMT | 7.87 | 0.15 | 0.27 | 5162 |
| 2026-01-14 | FDMT | 8.76 | 0.15 | 0.09 | 5112 |
| 2026-01-15 | FDMT | 7.61 | 0.16 | 0.02 | 4878 |
| 2026-01-16 | FDMT | 7.53 | 0.16 | 0.04 | 5027 |
| 2026-01-20 | FDMT | 7.63 | 0.17 | 0.00 | 1842 |
| 2026-01-21 | FDMT | 7.68 | 0.12 | 0.19 | 2472 |
| 2026-01-22 | FDMT | 8.1 | 0.12 | 0.00 | 2593 |
| 2026-01-23 | FDMT | 7.96 | 0.12 | 0.88 | 2601 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | FDMT | 7.98 | 41.3 | - | -3.26 |
| 2025-12-29 | FDMT | 7.67 | 41.3 | - | -3.26 |
| 2025-12-30 | FDMT | 7.60 | 41.3 | - | -3.26 |
| 2025-12-31 | FDMT | 7.48 | 41.3 | - | -3.26 |
| 2026-01-02 | FDMT | 7.32 | 41.3 | - | -3.26 |
| 2026-01-05 | FDMT | 7.30 | 41.3 | - | -3.26 |
| 2026-01-06 | FDMT | 7.19 | 41.3 | - | -3.26 |
| 2026-01-07 | FDMT | 7.78 | 41.3 | - | -3.26 |
| 2026-01-08 | FDMT | 7.30 | 41.3 | - | -3.26 |
| 2026-01-09 | FDMT | 7.52 | 41.3 | - | -3.26 |
| 2026-01-12 | FDMT | 7.51 | 41.3 | - | -3.26 |
| 2026-01-13 | FDMT | 7.88 | 41.3 | - | -3.26 |
| 2026-01-14 | FDMT | 8.76 | 41.3 | - | -3.26 |
| 2026-01-15 | FDMT | 7.61 | 41.3 | - | -3.26 |
| 2026-01-16 | FDMT | 7.53 | 41.3 | - | -3.26 |
| 2026-01-20 | FDMT | 7.63 | 41.3 | - | -3.26 |
| 2026-01-21 | FDMT | 7.69 | 41.3 | - | -3.26 |
| 2026-01-22 | FDMT | 8.11 | 41.3 | - | -3.26 |
| 2026-01-23 | FDMT | 7.97 | 41.3 | - | -3.26 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | FDMT | -0.25 | -1.48 | 9.66 |
| 2025-12-29 | FDMT | -0.25 | -1.48 | 9.66 |
| 2025-12-30 | FDMT | -0.25 | -1.48 | 9.66 |
| 2025-12-31 | FDMT | -0.25 | -1.48 | 9.66 |
| 2026-01-02 | FDMT | -0.25 | -1.48 | 9.66 |
| 2026-01-05 | FDMT | -0.25 | -1.45 | 9.66 |
| 2026-01-06 | FDMT | -0.25 | -1.45 | 9.66 |
| 2026-01-07 | FDMT | -0.25 | -1.45 | 9.66 |
| 2026-01-08 | FDMT | -0.25 | -1.45 | 9.66 |
| 2026-01-09 | FDMT | -0.25 | -1.45 | 9.66 |
| 2026-01-12 | FDMT | -0.26 | -1.45 | 9.66 |
| 2026-01-13 | FDMT | -0.25 | -1.45 | 16.68 |
| 2026-01-14 | FDMT | -0.25 | -1.45 | 16.68 |
| 2026-01-15 | FDMT | -0.25 | -1.45 | 16.68 |
| 2026-01-16 | FDMT | -0.25 | -1.45 | 16.68 |
| 2026-01-20 | FDMT | -0.25 | -2.05 | 16.68 |
| 2026-01-21 | FDMT | -0.25 | -2.05 | 16.68 |
| 2026-01-22 | FDMT | -0.25 | -2.05 | 17.30 |
| 2026-01-23 | FDMT | -0.25 | -2.05 | 17.30 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.69
Avg. EPS Est. Current Quarter
-0.53
Avg. EPS Est. Next Quarter
-0.93
Insider Transactions
-0.25
Institutional Transactions
-2.05
Beta
3
Average Sales Estimate Current Quarter
30
Average Sales Estimate Next Quarter
5
Fair Value
Quality Score
17
Growth Score
26
Sentiment Score
60
Actual DrawDown %
85.5
Max Drawdown 5-Year %
-95.2
Target Price
33.11
P/E
Forward P/E
PEG
P/S
3789.97
P/B
1.01
P/Free Cash Flow
EPS
-3.94
Average EPS Est. Cur. Y
-3.26
EPS Next Y. (Est.)
-3.48
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-174314.17
Relative Volume
0.54
Return on Equity vs Sector %
-84
Return on Equity vs Industry %
-68
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
4D Molecular Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 227
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in EmeryVille, California.
stock quote shares FDMT. – 4D Molecular Therapeutics Inc Stock Price stock today
news today FDMT. – 4D Molecular Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch FDMT. – 4D Molecular Therapeutics Inc yahoo finance google finance
stock history FDMT. – 4D Molecular Therapeutics Inc invest stock market
stock prices FDMT premarket after hours
ticker FDMT fair value insiders trading